Insider Transactions in Q2 2022 at Bei Gene, Ltd. (BGNE)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 27
2022
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
458
-100.0%
|
$81,066
$177.32 P/Share
|
|
Jun 22
2022
|
Qingqing Yi Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,692
+40.53%
|
-
|
|
Jun 22
2022
|
Thomas Malley Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,692
+33.08%
|
-
|
|
Jun 22
2022
|
Corazon (Corsee) D. Sanders Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,692
+40.53%
|
-
|
|
Jun 22
2022
|
Alessandro Riva Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,692
+50.0%
|
-
|
|
Jun 22
2022
|
Donald W. Glazer Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,692
+0.6%
|
-
|
|
Jun 22
2022
|
Anthony C Hooper Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,692
+40.53%
|
-
|
|
Jun 22
2022
|
Xiaodong Wang Director |
BUY
Grant, award, or other acquisition
|
Direct |
83,499
+1.42%
|
-
|
|
Jun 22
2022
|
Margaret Dugan Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,692
+50.0%
|
-
|
|
Jun 22
2022
|
Xiaobin Wu President, COO & GM China |
BUY
Grant, award, or other acquisition
|
Direct |
187,876
+15.98%
|
-
|
|
Jun 22
2022
|
Julia Aijun Wang Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
104,377
+29.83%
|
-
|
|
Jun 22
2022
|
Lai Wang Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
125,255
+7.66%
|
-
|
|
Jun 22
2022
|
John Oyler Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
334,009
+13.89%
|
-
|
|
Jun 22
2022
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
66,768
+33.07%
|
-
|
|
Jun 21
2022
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
1,010
-100.0%
|
$145,440
$144.36 P/Share
|
|
Jun 21
2022
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
723
-100.0%
|
$107,727
$149.01 P/Share
|
|
Jun 17
2022
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
578
-36.4%
|
$80,342
$139.6 P/Share
|
|
Jun 17
2022
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
445
-38.1%
|
$61,855
$139.4 P/Share
|
|
Jun 17
2022
|
Julia Aijun Wang Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
161
-100.0%
|
$21,896
$136.64 P/Share
|
|
Jun 06
2022
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
3,410
-100.0%
|
$480,810
$141.99 P/Share
|
|
Jun 06
2022
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
660
-100.0%
|
$93,720
$142.0 P/Share
|
|
May 17
2022
|
Lai Wang Global Head of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
1,233,947
+38.97%
|
$2,467,894
$2.89 P/Share
|
|
May 05
2022
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
6,725
-41.65%
|
$1,109,625
$165.7 P/Share
|